Showing results (91-100 of 143) with videos related to
Sort By:
Pageof 15
The Journal of Investigative Dermatology|May 25, 2012
Side population cells from human melanoma tumors reveal diverse mechanisms for chemoresistanceYuchun Luo, Lixia Z Ellis, Katiuscia Dallaglio, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 8, 2010
Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanomaKazuo Koyanagi, Steven J O'Day, Peter Boasberg, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 10, 2017
Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With TrametinibGeorgina V Long, Zeynep Eroglu, Jeffrey Infante, et al.Journal of Translational Medicine|November 23, 2012
Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusionAntoni Ribas, Jason A Chesney, Michael S Gordon, et al.Cancer Discovery|July 30, 2021
Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic MelanomaAntoni Ribas, Theresa Medina, John M Kirkwood, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2017
Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III TrialsDirk Schadendorf, Jedd D Wolchok, F Stephen Hodi, et al.Journal of Neuro-Oncology|June 18, 2018
Immune checkpoint inhibitors and radiosurgery for newly diagnosed melanoma brain metastasesTyler P Robin, Robert E Breeze, Derek E Smith, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 8, 2009
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanomaAxel Hauschild, Sanjiv S Agarwala, Uwe Trefzer, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 8, 2015
Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanomaPedram Gerami, Robert W Cook, Jeff Wilkinson, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 28, 2019
Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 TrialCeleste Lebbé, Nicolas Meyer, Laurent Mortier, et al.Pageof 15